Enhancement of an Artificial Lung for Ambulatory Respiratory Support

增强人工肺的动态呼吸支持

• 批准号: 10402813
• 负责人: Bartley P GriffIth
• 金额: $ 74.43万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-05 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10402813
• 关键词: Acute; Acute Disease; Acute respiratory failure; Air; Algorithms; Animal Experiments; Animals; Area; Biocompatible Materials; Biological; Blood; Blood gas; Carbon Dioxide; Chronic; Chronic lung disease; Destinations; Development; Devices; Electromagnetics; Evaluation; Excision; Exercise; Extracorporeal Membrane Oxygenation; Fuzzy Logic; Gases; Goals; Healthcare; Hemolysis; Hospitals; Hour; In Vitro; Injury; Legal patent; Liquid substance; Lung; Lung diseases; Measurement; Mechanical ventilation; Mechanics; Membrane; National Heart, Lung, and Blood Institute; Oxygen; Oxyhemoglobin; Patients; Performance; Physiological; Pump; Pump lung; Safety; Self-Help Devices; Software Validation; Source; Sterilization; Surface; System; Technology; Testing; Toxic effect; Transplantation; Validation; Venous; Weight; artificial lung; base; biomaterial compatibility; commercialization; design; exhaust; healing; improved; in vivo; light weight; manufacturability; manufacturing process; multidisciplinary; new technology; novel; portability; pre-clinical; regenerative therapy; respiratory; respiratory assist; response; sheep model; sterility testing

Acute and chronic end-stage lung diseases (ESLD) are increasing healthcare problems. Currently, when mechanical ventilation fails only extracorporeal membrane oxygenation (ECMO) with components designed and qualified for a few hours is available. Current ECMO systems are often associated with serious complications and generally are restricted to bedside use. A wearable, biocompatible integrated pump-lung would offer significant advantages to patients over existing options. Such a device would pose a prolonged ambulatory platform for natural lung healing from acute injury, a bridge to transplant or destination therapy, or for novel lung regenerative therapies. With support from the NHLBI, we have made remarkable progress in development of a wearable artificial pump-lung system (APLS) for ambulatory respiratory support. The goal of this renewal application is to develop a new class of gas exchange device with adaptive physiologic control for a wearable artificial lung system. We propose to develop unique strategies to reduce the sizes of gas exchanger devices and associated drive consoles and to provide adaptive respiratory support to ambulating ECMO patients. Three specific aims of the proposal are: (1) to develop a small-sized and multifunctional membrane respiratory assist device (MRAD) for ECMO therapy in the ambulatory setting. The novel MRAD will include a dual chamber gas exchanger (DCGE) for blood and gas flows with an integrated centrifugal pump; (2) to develop a lightweight console for the MRAD with auto-adaptive control based on the gas exchange demand of an ambulating patient. The portable console will be less than 20 lbs and can be placed into a backpack; and (3) to conduct in-vitro regulatory qualification tests and chronic (30-day) in-vivo animal experiments to assess the long-term function, biocompatibility, and durability of the MRAD and its biologic effect on the animal. The efficiency of the new gas exchange device will reduce its size and its console by near 30%. The reduced console size and weight will reduce its burden to the user and will permit its configuration into a backpack design as well as a small roller case. Completion of aims will redefine the technology appropriate for broadened use of ambulatory ECMO and for its out-of-hospital use.

急性和慢性终末期肺病（ESLD）正在增加医疗保健问题。目前，当 机械通气仅在体外膜肺氧合（ECMO）失败， 并有资格在几个小时内提供。目前的ECMO系统通常与严重的 并发症，并且通常限于床边使用。一种可穿戴的、生物相容的集成泵肺， 将为患者提供优于现有选择的显著优势。这样的设备将造成长期的 用于急性损伤的自然肺愈合的流动平台，移植或目标治疗的桥梁，或 用于新型肺再生疗法。在NHLBI的支持下，我们在以下方面取得了显著进展： 开发一种用于非卧床呼吸支持的可穿戴人工泵肺系统（APLS）。的目标 该更新申请是开发一种具有自适应生理控制的新型气体交换装置， 一种可穿戴的人工肺系统 我们建议开发独特的策略，以减少气体交换器设备和相关驱动器的尺寸 控制台，并提供自适应呼吸支持，走动ECMO患者。三个具体目标 建议：（1）开发一种小型多功能膜呼吸辅助装置（MRAD）， 门诊环境下的ECMO治疗。新的MRAD将包括一个双室气体交换器（DCGE） 用于血液和气体流动的集成离心泵;（2）开发用于MRAD的轻型控制台 具有基于走动患者的气体交换需求的自适应控制。便携式控制台 将小于20磅，可放入背包;（3）进行体外监管确认 测试和慢性（30天）体内动物实验，以评估长期功能、生物相容性和 MRAD的耐久性及其对动物的生物效应。 新的气体交换装置的效率将使其尺寸和控制台减少近30%。减少 控制台的尺寸和重量将减少其负担的用户，并将允许其配置到背包 设计以及一个小滚筒箱。目标的完成将重新定义适用于以下方面的技术： 扩大了门诊ECMO的使用范围，并扩大了其院外使用范围。